Ann: Independent review supports development of BIT225, page-9

I'd have liked to see some stats on the significance on the difference between BIT225 and placebo effect given the margin is relatively small. We really need to know if it is significant.

Other than that we wait and see. August isn't too long to wait compared with how long we've been waiting this far.

Also I note: The DSMC also noted that more patients than expected are failing treatment with the new DAAs and that this population, which has very limited choices, may be an area of interest for BIT225 given its novel and different anti-
viral mechanism of action.